Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0006 |
mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.003 |
mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.094 | 0.004 |
mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.096 | 0.006 |
mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.007 |